Drug efficacy
Olaparib halts tumour growth in advanced prostate cancer
Source: Wikimedia Commons
In a phase II clinical trial, of 15 men with prostate cancer that had detectable DNA repair mutations, 13 responded to olaparib
Olaparib was approved by the US Food and Drug Administration in December 2014 for the treatment of women with ovarian cancer who have inherited BRCA mutations.
Now, researchers have shown that the drug also benefits men with prostate cancer.
In a phase II clinical trial, 16 of 49 patients with treatment-resistant advanced prostate cancer responded to olaparib. Of 15 men with detectable DNA repair mutations, 13 responded to olaparib, according to research[1] reported at the American Association of Cancer Research conference in Philadelphia on 21 April 2015.
The investigators, led by a team from the Institute of Cancer Research and the Royal Marsden NHS Trust, London, now plan to test the drug exclusively in men with prostate cancer that has detectable DNA repair mutations.
Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2015.20068443
Recommended from Pharmaceutical Press
- Previous
- Next
FASTtrack: Pharmacology
FASTtrack: Pharmacology is a study guide providing an account of drug action, as well as dealing with molecular pharmacology at a more advanced level.
£28.00Buy now
Print 
PDF
Have your say
For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.